Expression of the Flp proteins by Haemophilus ducreyi is necessary for virulence in human volunteers by Janowicz, Diane M et al.
RESEARCH ARTICLE Open Access
Expression of the flp proteins by Haemophilus
ducreyi is necessary for virulence in human
volunteers
Diane M Janowicz
1*, Sean A Cooney
1, Jessica Walsh
2, Beth Baker
3, Barry P Katz
1, Kate R Fortney
1, Beth W Zwickl
1,
Sheila Ellinger
1 and Robert S Munson Jr
3,4
Abstract
Background: Haemophilus ducreyi, the causative agent of the sexually transmitted disease chancroid, contains a flp
(fimbria like protein) operon that encodes proteins predicted to contribute to adherence and pathogenesis. H.
ducreyi mutants that lack expression of Flp1 and Flp2 or TadA, which has homology to NTPases of type IV
secretion systems, have decreased abilities to attach to and form microcolonies on human foreskin fibroblasts
(HFF). A tadA mutant is attenuated in its ability to cause disease in human volunteers and in the temperature
dependent rabbit model, but a flp1flp2 mutant is virulent in rabbits. Whether a flp deletion mutant would cause
disease in humans is not clear.
Results: We constructed 35000HPΔflp1-3, a deletion mutant that lacks expression of all three Flp proteins but has
an intact tad secretion system. 35000HPΔflp1-3 was impaired in its ability to form microcolonies and to attach to
HFF in vitro when compared to its parent (35000HP). Complementation of the mutant with flp1-3 in trans restored
the parental phenotype. To test whether expression of Flp1-3 was necessary for virulence in humans, ten healthy
adult volunteers were experimentally infected with a fixed dose of 35000HP (ranging from 54 to 67 CFU) on one
arm and three doses of 35000HPΔflp1-3 (ranging from 63 to 961 CFU) on the other arm. The overall papule
formation rate for the parent was 80% (95% confidence interval, CI, 55.2%-99.9%) and for the mutant was 70.0%
(95% CI, 50.5%-89.5%) (P = 0.52). Mutant papules were significantly smaller (mean, 11.2 mm
2) than were parent
papules (21.8 mm
2) 24 h after inoculation (P = 0.018). The overall pustule formation rates were 46.7% (95% CI 23.7-
69.7%) at 30 parent sites and 6.7% (95% CI, 0.1-19.1%) at 30 mutant sites (P = 0.001).
Conclusion: These data suggest that production and secretion of the Flp proteins contributes to microcolony
formation and attachment to HFF cells in vitro. Expression of flp1-3 is also necessary for H. ducreyi to initiate
disease and progress to pustule formation in humans. Future studies will focus on how Flp proteins contribute to
microcolony formation and attachment in vivo.
Background
The tad (tight adherence) locus is present in many
Gram-positive and Gram-negative bacteria as well as the
Archaea and likely represents an ancient subtype of type
IV secretion systems that was horizontally transferred to
many bacterial species early in the course of evolution.
The tad genes are located on a mobile genomic island
coined “the widespread colonization island” by Figurski
and coworkers [1]. The functions of the tad locus gene
products have been best described for Aggregatibacter
(formerly Actinobacillus) actinomycetemcomitans,w h e r e
they are essential for adherence, biofilm formation, and
pathogenesis. The Tad proteins are predicted to form a
macromolecular transport system for the assembly and
secretion of fimbria or pili, which mediate adherence of
the organism to different surfaces [2].
Haemophilus ducreyi is a gram-negative coccobacillus
that causes the sexually transmitted genital ulcer disease
chancroid, which is a public health concern because it
increases the risk of transmission and acquisition of
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12.8 kb flp (fimbria like protein) operon with 15 genes
(flp1-flp2-flp3-orfBC-rcpAB-orfD-tadABCDEFG)t h a t
encode products with homology to proteins encoded by
the tad locus in A. actinomycetemcomitans [3,4]. H.
ducreyi mutants that lack expression of either Flp1 and
Flp2, which encode fimbria like proteins, or tadA, which
has homology to NTPases of type IV secretion systems,
have decreased abilities to attach to human foreskin
fibroblasts (HFF) and to form microcolonies on HFF
[4,5]. A mutant deficient in the expression of tadA was
significantly but partially attenuated in the temperature
dependent rabbit model of experimental chancroid,
while a mutant lacking flp1 and flp2 expression was
fully virulent in this model [4,5]. Thus, whether Flp-
Tad-mediated adherence and/or microcolony formation
are critical factors in the virulence of H. ducreyi is
unclear [6].
In experimental and natural infection in humans, H.
ducreyi forms aggregates, the first step in microcolony
formation, and colocalizes with polymorphonuclear leu-
kocytes and macrophages, which fail to ingest the
organism. In human inoculation experiments, a tadA
mutant is highly attenuated for virulence; whether the
observed attenuation is due to the lack of secretion of
the Flp proteins or other unidentified effectors by the
tad locus is unclear [5]. Given the discrepancy in viru-
lence between the tadA mutant and the flp1flp2 mutant
in the temperature dependent rabbit model [5], here we
constructed and characterized a flp1-3 deletion mutant.
We tested the flp1-3 mutant for its ability to cause dis-
ease in human volunteers and its ability to form micro-
colonies and adhere to human fibroblasts. Our data
indicate that expression of Flps is required for virulence
and that Flp-Tad mediated adherence correlates with
the virulence of H. ducreyi in humans. To our knowl-
edge, this study is the first to provide definitive proof
that expression of the Flp proteins is required for the
virulence of a bacterial pathogen in humans.
Results
Construction and characterization of 35000HPΔflp1-3
An unmarked, in frame deletion mutant of the flp1, flp2,
and flp3 genes was constructed in 35000HP using
recombineering technology and designated
35000HPΔflp1-3 [7,8]. Sequence analysis of
35000HPΔflp1-3 confirmed that flp1, flp2 and flp3 had
been replaced by a short ORF that consisted of the
upstream region of flp1, the start codon of flp1,8 1b p
encoding a scar peptide, and the last 21 bp of flp3,
including its stop codon. By qRT-PCR, the expression
levels of tadA and tadG, two genes downstream of flp3,
were similar in 35000HPΔflp1-3 compared to 35000HP
(data not shown), suggesting that the remainder of the
flp operon was normally transcribed. 35000HP and
35000HPΔflp1-3 demonstrated identical growth rates in
broth (data not shown). The LOS profiles and OMP pat-
t e r n sa sa n a l y z e db yS D S - P A G Ew e r es i m i l a rf o rt h e
mutant and the parent (data not shown).
Human inoculation experiments
To determine whether the Flp proteins play a role in
pathogenesis, 35000HPΔflp1-3 was compared with
35000HP for virulence using a mutant parent compari-
son trial in the human model of infection. Ten healthy
adults (six males, four females; 5 Caucasian, 5 black; age
range 32 to 59; mean age ± standard deviation, 48 ± 9
years) volunteered for the study. Three subjects (volun-
teers 333, 334, and 335) were inoculated in the first
iteration, three subjects (volunteers 336, 337, and 338)
in the second iteration, one subject (volunteer 341) in
the third iteration and three subjects (volunteers 342,
343, and 344) in the fourth iteration. In the first itera-
tion, each subject was infected with a fixed EDD (61
CFU) of 35000HP at three sites on one arm and varying
EDDs (63, 125, and 249 CFU) of 35000HPΔflp1-3 on
t h eo t h e ra r m( T a b l e1 ) .S i n c et h ea b i l i t yo ft h em u t a n t
to form pustules seemed impaired (Table 1), we
increased the dose of the mutant in subsequent itera-
tions, as per protocol. In the second iteration, volunteers
were inoculated with 65 CFU of the parent and 66, 131,
and 262 CFU of the mutant (Table 1). In the third itera-
tion, the volunteer was infected with 67 CFU of
35000HP and 240, 480, and 961 CFU of the mutant
(Table 1). In the fourth iteration, volunteers were inocu-
lated with 54 CFU of the parent and 104, 208 and 415
CFU of the mutant (Table 1).
The overall papule formation rate for the parent was
80% (95% confidence interval, CI, 55.2%-99.9%) at 30
sites and for the mutant was 70.0% (95% CI, 50.5%-
89.5%) at 30 sites (P = 0.52). Mutant papules were sig-
nificantly smaller (mean, 11.2 mm
2) than were parent
papules (21.8 mm
2) 24 h after inoculation (P =0 . 0 1 8 ) .
The overall pustule formation rates were 46.7% (95% CI
23.7-69.7%) at 30 parent sites and 6.7% (95% CI, 0.1-
1 9 . 1 % )a t3 0m u t a n ts i t e s( P = 0.001). Mutant pustules
formed at only two sites in one volunteer. These results
indicate that expression of one or more of the flp1, flp2,
and flp3 genes in the context of the intact secretion/
assembly complex is necessary for H. ducreyi to initiate
disease and progress to pustule formation in humans.
H. ducreyi was recovered intermittently from surface
cultures. Of the 30 sites that were inoculated with the
parent, 11 (36.7%) yielded at least one positive surface
culture, while 3 of 30 mutant sites (10.0%) yielded a
positive surface culture (P = 0.019). All colonies recov-
ered from sites inoculated with the parent (n = 626) or
the mutant (n = 39) and colonies from the parent (n =
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presence of flp1-flp2-flp3 and fgbA sequences by colony
hybridization. The fgbA probe hybridized to all the colo-
nies, while the flp1-2-3 probe hybridized only to the
colonies obtained from the parent inoculated sites or
the parent inocula. Thus, there was no cross contamina-
tion of mutant and parent sites during the course of the
trial.
Deletion of flp1flp2flp3 affects attachment of 35000HP to
HFF cells and microcolony formation
To confirm the phenotype of 35000HPΔflp1-3,w ec o m -
plemented 35000HPΔflp1-3 in trans by electroporating
it with plasmid pJW1, which encodes the Flp1, Flp2 and
Flp3. flp1, flp2, and flp3 encode proteins with predicted
molecular weights of 9.3 kDa, 8.9 kDa, and 9.9 kDa,
respectively. Western blot analysis with a polyclonal sera
that binds to Flp1 and Flp2 confirmed that
35000HPΔflp1-3(pLSSK) lacked the ability to express
the Flp1 and Flp2 proteins (Figure 1, lane 2) compared
to 35000HP(pLSSK) (Figure 1, lane 1). Complementa-
tion of 35000HPΔflp1-3 with plasmid pJW1 resulted in
restoration of the expression of the Flp1 and Flp2 pro-
teins as determined by Western blot (Figure 1, lane 3).
35000HP(pLSSK), 35000HPΔflp1-3(pLSSK), and
35000HPΔflp1-3(pJW1) were also tested for their abilities
to bind confluent HFF monolayers. 35000HPΔflp1-3
(pLSSK) significantly attached to HFF cells at lower levels
(geomean ± standard deviation, 26.0% ± 15.0%) than did
35000HP(pLSSK) (100% ± 29.0%) (P =0 . 0 1 8 )( F i g u r e2 ) .
35000HPΔflp1-3(pJW1) adhered to HFF cells (92.0% ±
18.0%) at significantly higher levels than 35000HPΔflp1-3
(pLSSK) (P = 0.010) and at similar levels as 35000HP
(pLSSK) (P = 0.32) (Figure 2).
Table 1 Response to inoculation of live H.ducreyi strains
Volunteer Gender
a Days of
Observation
Isolate
b Dose (cfu) No. of
Initial
Papules
No. of
Pustules
333 F 14 P 61 3 1
M 63-249 2 0
334 M 9 P 61 3 0
M 63-249 2 0
335 M 7 P 61 3 1
M 63-249 3 0
336 F 6 P 65 0 0
M 66-261 3 0
337 M 7 P 65 0 0
M 66-261 1 0
338 F 8 P 65 3 2
M 66-261 0 0
341 M 8 P 67 3 2
M 240-961 3 2
c
342 F 7 P 54 3 3
M 104-415 3 0
343 M 6 P 54 3 3
M 104-415 2 0
344 M 7 P 54 3 2
M 104-415 2 0
a, F = female, M = male; b, P = parent, M = mutant
Figure 1 Western Blot analysis of Flp1 and Flp2 expression by
wild type, mutant, and complemented H. ducreyi strains.
Whole-cell lysates were probed with polyclonal rabbit Flp1
antiserum as the primary antibody. Lanes: 1, wild-type 35000HP
(pLSSK); 2, 35000HPΔflp1-3(pLSSK); 3, 35000HPΔflp1-3(pJW1).
Molecular markers are shown on the left.
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35000HPΔflp1-3(pJW1) were also compared for their
abilities to form microcolonies after 24 h incubation
with confluent HFF monolayers. 35000HP formed
numerous, densely populated microcolonies on the sur-
faces of HFF cells [4] (Figure 3A). 35000HPΔflp1-3
(pLSSK) formed sparse and very small microcolonies
(Figure 3B) when compared to 35000HP; the comple-
mented mutant demonstrated a restored phenotype
similar to 35000HP(pLSSK) (Figure 3C). Thus, comple-
mentation of the mutant restored the parental
phenotypes.
Discussion
For this study, we focused on whether the expression of
the Flp proteins was necessary for virulence of H.
ducreyi. We constructed an unmarked, in frame deletion
mutant lacking the flp1flp2flp3 genes in 35000HP using
a recombineering strategy [8,9] and found that
35000HPΔflp1-3 was significantly impaired in its ability
to cause disease in the human model of infection. flp1-3
joins h g b A ,d s r A ,n c a A ,l s p A 1 - l s p A 2 ,p a l ,t a d As a p B C
and cpxA as the ninth gene required for full virulence
by H. ducreyi in the human inoculation experiments
[9,10] (unpublished observations).
The flp-tad gene cluster is constitutively transcribed as
a single polycistronic operon in vitro [4]. Relative to its
expression during in vitro growth, tadA transcripts are
enriched in experimental pustules, suggesting that the
flp-tad operon is upregulated in vivo [11]. CpxRA is the
only obvious intact two-component signal transduction
system contained in H. ducreyi. Transcription of flp1-3
and several other major virulence determinants are
negatively regulated by conditions that favor phosphory-
lation of CpxR [9,12,13]. Purified recombinant CpxR
interacts with the promoter regions of the flp operon in
electrophoretic mobility shift assays [13]. Deletion of
cpxA leads to loss of CpxA phosphatase activity, acti-
vates CpxR, and cripples the ability of H. ducreyi to
infect humans [9]. In contrast, a cpxR deletion mutant
has no effect on or upregulates the expression of viru-
lence determinants and is fully virulent in human volun-
teers [13]. Taken together, the data suggest that the flp-
tad operon may be upregulated in vivo due to downre-
gulation of CpxRA.
The human inoculation experiments are limited in
that we are precluded by several regulatory bodies from
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Figure 2 Quantitative measurement of the binding of wild
type, mutant, and complemented H. ducreyi strains to HFF
cells. Assays were performed as described in Materials and
Methods. The data represented are a composite of five separate
experiments. Bars: 1, wild-type 35000HP(pLSSK); 2, 35000HPΔflp1-3
(pLSSK); 3, 35000HPΔflp1-3(pJW1).
Figure 3 Microcolony formation by (A) wild type 35000HP(pLSSK), (B) flp1-3 mutant 35000HPΔflp1-3(pLSSK), and (C) complemented
flp1-3 mutant 35000HPΔflp1-3 (pJW1). Magnification ×400.
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ever, complementation of 35000HPΔflp1-3 in trans
restored the ability of the mutant to form microcolonies
and bind to HFF cells, suggesting that the phenotype of
the mutant is due to the deletion of the flp genes. In the
human inoculation experiments, we use 35000HP to
examine the role of virulence factors in H. ducreyi
pathogenesis. There are two classes of H. ducreyi strains,
which express different immunotypes and proteomes
[14,15]. Although we were able to amplify flp1-3 alleles
from six class I and three class II strains (data not
shown), attempts to sequence the amplicons were
unsuccessful, so we do not know if there is a difference
in the flp genes in the class I and class II strains.
35000HP is a class I strain; whether the Flp proteins
p l a yar o l ei nt h ev i r u l e n c eo fc l a s sI Is t r a i n si s
unknown.
We previously reported that a tadA mutant is attenu-
ated for pustule formation in the human challenge
model [5]. However, the tadA mutant, but not a flp1flp2
double mutant, is attenuated in the rabbit model of
chancroid [4,5]. Nika et al previously reported that both
the flp1flp2 mutant and the tadA mutant demonstrate
decreased abilities to attach to HFF cells and form fewer
microcolonies on HFF cells [4]. These data suggested
that microcolony formation by itself is not a virulence
factor for H. ducreyi. Although H. ducreyi does not
appear to co-localize with fibroblasts in experimental or
natural chancroid [16,17], our data indicate that adher-
ence to HFF cells in vitro correlates with the virulence
of H. ducreyi in humans. Similarly, both flp1 and tadA
mutants fail to colonize or cause disease in a rat infec-
tion model with A. actinomycetemcomitans [1], and
both flp1 mutant and tadD mutants of Pasteurella mul-
tocida are attenuated in the septicemic mouse model
[18,19].
In A. actinomycetemcomitans, Flp pili are assembled as
bundles of long fibers in which Flp1 is the major struc-
tural component [3,20]. However, there is no evidence
that the Flp proteins are assembled into a pilus-like
structure in H. ducreyi [4]. Several bacterial species
including A. actinomycetemcomitans have two flp genes
[2]. H. ducreyi contains three flp genes, which have
between 50-80% similarity to one another [4]. Deletion
of flp1 and flp2 results in decreased adherence of H.
ducreyi to HFF cells and subsequent microcolony for-
mation [4]; the function of Flp3 is unclear.
In vitro, H. ducreyi forms microcolonies, a key step in
biofilm formation. In vivo, H. ducreyi forms aggregates
and colocalizes with macrophages, PMNs, collagen and
fibrin [16,17]. H. ducreyi contains a luxS homologue
that has autoinducer (AI-2) activity in a Vibrio harveyi-
based reporter system, and a luxS mutant is partially
attenuated for virulence in human volunteers [21].
Taken together, these data suggest that the formation of
microcolonies, aggregates and quorum sensing mechan-
isms may be important for H. ducreyi pathogenesis.
Whether the Flp proteins contribute to this process by
mediating attachment to host cells or initiating micro-
colony formation in the skin remains a subject for
future investigation.
Conclusions
We have constructed an unmarked, in frame deletion
mutant lacking the flp1flp2flp3 genes in H. ducreyi
strain 35000HP. The deletion mutant, 35000HPΔflp1-3,
has an intact tad secretion system. Our data show that
production and secretion of the Flp proteins contributes
to microcolony formation and attachment of 35000HP
to HFF cells in vitro. Complementation of the mutant
with flp1-3 in trans restored the parental phenotype.
Additionally, expression of Flp1-3 is necessary for H.
ducreyi to initiate disease and progress to pustule for-
mation in humans. Future studies will focus on how Flp
proteins contribute to microcolony formation and
attachment in vivo.
Methods
Bacteria and culture conditions
35000HP is a human-passaged (HP) variant of strain
35000 and has been reported previously [22]. H. ducreyi
strains were grown on chocolate agar plates supplemen-
ted with 1% IsoVitaleX at 33°C in 5% CO2.F o rt h e
human inoculation experiments, H. ducreyi was grown
in a protease peptone broth-based medium supplemen-
ted with 50 μg of hemin per ml, 1% IsoVitaleX and 5%
heat-inactivated fetal calf serum (FCS) as described [23]
or in a Columbia broth based medium with 2.5% heat-
inactivated FCS for other experiments. When appropri-
ate, the media were supplemented with chlorampheni-
col, spectinomycin, or kanamycin at 0.3 μg/ml, 200 μg/
ml, or 20 μg/ml, respectively, to maintain plasmids or
select for chromosomal integration of antibiotic resis-
tance cassettes. E. coli strains were grown in Luria-Ber-
tani broth or plates at 37°C, except for strain DY380,
which was grown or maintained at 32°C and induced to
express l recombinase at 42°C.
Construction and characterization of a flp1-3 mutant of
strain 35000HP
An unmarked, in frame deletion mutant of the flp1, flp2,
and flp3 genes was made in H. ducreyi strain 35000HP
using Flippase (FLP) recombinase technology as described
previously [8,9]. Briefly, two 70 bp primers, P1 and P2,
were designed for construction of a cassette (Table 2). The
3’ end of each of these primers contained 20 bp comple-
mentary to regions 5’ and 3’ of a spectinomycin cassette
flanked by FLP Recognition Target (FRT) sites in
Janowicz et al. BMC Microbiology 2011, 11:208
http://www.biomedcentral.com/1471-2180/11/208
Page 5 of 8pRSM2832 [8]. The 5’ portion of the P1 and P2 primers
were homologous to regions 5’ and 3’ of H. ducreyi flp1
and flp3, respectively. PCR of pRSM2832 with P1 and P2
yielded a 2 Kb amplicon that contained the spectinomycin
cassette flanked by FRT sites and 50 bp of DNA homolo-
gous to regions 5’ and 3’ of H. ducreyi flp1 and flp3,
respectively. This amplicon was electroporated into E. coli
DY380 harboring a cosmid size pBeloBAC clone contain-
ing the flp operon and flanking DNA. After induction of l
recombinase in this strain, spectinomycin-resistant clones
were isolated. One clone was further characterized to
demonstrate that the flp1, -2 and -3 genes were replaced
with the spectinomycin cassette, with the exception of the
flp1 start codon and the terminal 21 bp of the flp3 ORF.
The construct was confirmed by sequence analysis.
The pBeloBAC clone containing the insertion/deletion
mutation in the flp genes was used as a template for
PCR. The amplicon containing the insertionally inacti-
vated flp1flp2flp3 genes and approximately 500 bp of
flanking DNA 5’ and 3’ to the cassette was ligated into
the suicide vector, pRSM2072, and then electroporated
into 35000HP. Cointegrates were selected by growth on
spectinomycin, then resolved by passage on plates con-
taining spectinomycin and 5-bromo-4-chloro-3-indoly-
b-D-galactopyranoside (X-Gal) [24]. Allelic exchange
was confirmed by colony PCR.
To make an unmarked mutant, the plasmid,
pRSM2975, which contains a temperature sensitive
replicon, a kanamycin resistance cassette, and FLP
recombinase under the control of the tet repressor, was
transformed into the mutant [9]. Transformants were
selected and maintained at 32°C on chocolate agar con-
taining kanamycin. The FLP recombinase was induced
to catalyze excision of the spectinomycin cassette result-
ing in a short unmarked ORF in place of the flp1, flp2
and flp3 genes and the plasmid was cured as described
previously [9]. Colonies were replica plated on chocolate
agar containing no antibiotics, 200 μg/ml of spectinomy-
cin, and 20 μg/ml of kanamycin to identify clones that
lost both the temperature sensitive plasmid and the
spectinomycin cassette. The plasmid and the spectino-
mycin cassette were lost in 3/120 (2.5%) of the clones
tested. One clone that had a deletion of the expected
size by colony PCR was designated 35000HPΔflp1-3.
Lipooligosaccharide (LOS) and outer membrane pro-
teins (OMPs) were prepared from 35000HP and
35000HPΔflp1-3 and were analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, as described
[25]. The growth of parent and mutant in broth cultures
were also compared.
RNA isolation and Real Time PCR
Bacterial RNA was prepared from mid-log phase organ-
isms by using TRIzol Reagent (Invitrogen) according to
manufacturer’s instructions. After isolation, RNA was
treated twice with DNaseI (Ambion) for 1 hour at 37°C
and then purified by using the RNeasy system (Qiagen).
Samples were checked by Agilent analysis. After opti-
mizing primers so that their efficiencies were greater
than 95%, we examined the level of transcript expression
in RNA isolated from 35000HP and 35000HPΔflp1-3.
Using each bacterial RNA, and either the tadA primers
( P 3a n dP 4 )( T a b l e2 )o rt h etadG (P5 and P6) primers
(Table 2) and SYBR Green, reactions were performed in
triplicate using an ABI PRISM 7000 Sequence Detector
(Applied Biosystems). Data were expressed as fold
change of tadA and tadG in the mutant relative to the
parent.
Complementation of 35000HPΔflp1-3
To complement 35000HPΔflp1-3 in trans, the flp1, flp2
and flp3 ORFs were amplified using the P7 primer with
a BamH1 linker and the P8 primer with an XhoI linker.
The resulting 1.58-kb amplicon was ligated into pCR-
Table 2 Primers used in this study
Primer Sequence
P1 TAACCTAAAAAAACAACATAATTTATTTTATATTTGGAGAAAAAGATATGATTCCGGGGATCCGTCGACC
P2 GTATATATGGCACATATAAATTATGTGTTTTATAATCTACCTTTATTGAATGTAGGCTGGAGCTGCTTCG
P3 CGGTCACGATGGTTCAATGTCT
P4 AGCGTTTGACATCATCACCATACT
P5 TGCCTACAGCTCAAGTCACGTAA
P6 CCACTCGAAAGCGAAACTTGT
P7 CATCTCGAGCGCCACACTATCCAC
P8 CACTCTAGATTATAATCTACCTTT
P9 GGCTTAATTGCAGTCGCAGTTGCT
P10 GTGCAGCTTTACCTACTCCTCCTT
P11 ACTCCGCAGCTGATGCAATGAAAG
P12 CAAGCTTATCGATACCGTCGACCT
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were selected on Luria-Bertani plates supplemented with
kanamycin (50 μg/ml). The 1.58 kb insert was released
from the vector by digestion with BamHI and XhoI,
ligated into pLSSK [26], and then transformed into E.
coli DH5a. The plasmid was confirmed by restriction
mapping and designated pJW1. H. ducreyi
35000HPΔflp1-3 was electroporated with pJW1. As con-
trols, 35000HP and 35000HPΔflp1-3 were electroporated
with pLSSK. Transformants were selected on chocolate
agar plates containing streptomycin (50 μ/ml) and trans-
formants were saved and designated 35000HPΔflp1-3
(pJW1), 35000HP(pLSSK) and 35000HPΔflp1-3(pLSSK).
SDS-PAGE and Western Blot Analysis
Whole cell lysates were prepared from 35000HPΔflp1-3
(pJW1), 35000HPΔflp1-3(pLSSK), and 35000HP(pLSSK)
and subjected to SDS-PAGE as previously described
[27]. In Western Blot analysis, whole cell lysates were
probed with rabbit polyclonal sera that bind to Flp1 and
Flp2 (kindly provided by Eric J. Hansen) as described
elsewhere [4].
Human inoculation protocol
Stocks of 35000HP and 35000HPΔflp1-3 were prepared
according to the US Food and Drug Administration
guidelines (BB-IND 13046). For the human inoculation
protocol, healthy adult male and female volunteers over
21 years of age were recruited for the study. Subjects
gave informed consent for participation and for human
immunodeficiency virus (HIV) serology, in accordance
with the human experimentation guidelines of the U.S.
Department of Health and Human Services and the
institutional ethics committee of Indiana University-Pur-
due University of Indianapolis. The experimental proto-
col, preparation and inoculation of the bacteria,
calculation of the estimated delivered dose (EDD), and
clinical observations were all done exactly as described
previously [10,28]. Subjects were observed until they
reached clinical endpoint, which was defined as resolu-
tion of all sites, development of a pustule that was either
painful or > 6 mm in diameter, or 14 days after inocula-
tion. Subjects were then treated with one dose of oral
ciprofloxacin as described [29]. Comparison of papule
and pustule formation rates for the two strains were
performed using a logistic regression model with gener-
alized estimating equations (GEE) to account for the
correlation among sites within the same individual, as
previously described [28]. The GEE sandwich estimate
for the standard errors was used to calculate 95% confi-
dence intervals (95% CI) for these rates.
To confirm that the strains contained or lacked the
flp1flp2flp3 genes, colonies from the inocula, surface
cultures and biopsy specimens were replica plated and
grown on nitrocellulose filters. Filters were probed with
amplicons corresponding to either the fgbA (fibrinogen
binder A) gene or the deleted portion of the flp1flp2flp3
genes. The flp1flp2flp3 and the fgbA probes were made
using primers P9 and P10 and primers P11 and P12,
respectively. Probes were labeled with digoxigenin using
the DIG DNA Labeling Kit (Roche Applied Sciences,
Penzberg, German) and detected with the DIG Easy
Hyb protocol (Roche Applied Sciences) according to the
manufacturer’s instructions.
Adherence assays
Adherence of bacteria to HFF was measured quantita-
tively as described previously[ 4 ] .B r i e f l y ,2 4 - w e l lt i s s u e
culture plates (Costar, Corning, N.Y.) were inoculated
with 10
5 HFF/well and grown to confluence.
35000HPΔflp1-3(pJW1), 35000HPΔflp1-3(pLSSK), and
35000HP(pLSSK) were grown in Columbia broth to an
OD660 between 0.4 and 0.6 and harvested by centrifuga-
tion. Bacterial pellets were suspended using HFF med-
ium and approximately 10
6 CFU were added to
individual wells containing confluent HFF, centrifuged
at 500 × g, and incubated for 2 h at 33°C. After nonad-
herent bacteria were removed by washing three times
with HFF medium, 1 ml of trypsin-EDTA (Invitrogen)
solution was added to each well and the plate was incu-
bated for 5 min to liberate the bound bacteria. Serial
dilutions of well contents were plated to quantitate
HFF-bound bacteria. Percent adherence was calculated
as the ratio of HFF-bound bacteria to initial CFU added
per well. A paired Student’s t test was used for the com-
parison of strains’ abilities to attach to HFF cells.
Microcolony formation assays
Confluent HFF monolayers were prepared and 35000HP
(pLSSK), 35000HPΔflp1-3(pLSSK), and 35000HPΔflp1-3
(pJW1) were grown as described for the adhesion assays.
Bacterial pellets were resuspended in HFF medium to an
OD660 of 0.1. Approximately 10
6 CFU for each strain
was added to individual wells of confluent HFF cells,
centrifuged at 500 × g for 4 min, and incubated for 24 h
at 33°C. Wells were washed three times with 1 ml HFF
medium and then stained with crystal violet [0.25% (wt/
vol) crystal violet, 20% (vol/vol) methanol, 0.9% (wt/vol)
NaCl, 0.02 M Tris-HCl (pH 7.5)] for 20 min at room
temperature.
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